Predictive biomarkers: A paradigm shift towards personalized cancer medicine

Nature Reviews Clinical Oncology

Volumn 8, Issue 10, 2011, Pages 587-596

  La Thangue, Nicholas B ^a   Kerr, David J ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; BEVACIZUMAB; BIOLOGICAL MARKER; BORTEZOMIB; CARBOPLATIN; CETUXIMAB; CRIZOTINIB; CYCLOPHOSPHAMIDE; DASATINIB; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; ESTROGEN RECEPTOR; GEFITINIB; GEMCITABINE; IMATINIB; INIPARIB; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NILOTINIB; OLAPARIB; PACLITAXEL; PANITUMUMAB; RETINOIC ACID; TAMOXIFEN; TRASTUZUMAB; VELIPARIB; VEMURAFENIB;

ALK GENE; BCR ABL GENE; BREAST CANCER; CANCER SURVIVAL; CANCER THERAPY; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; DISEASE FREE SURVIVAL; EGFR GENE; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL TOXICITY; GENE; GENE AMPLIFICATION; GENE REARRANGEMENT; GENE TRANSLOCATION; GENETIC SCREENING; GLIOBLASTOMA; HER2 GENE; HUMAN; LEUKEMIA RELAPSE; LUNG NON SMALL CELL CANCER; MELANOMA; NEPHROTOXICITY; ONCOGENE K RAS; OVERALL SURVIVAL; PANCREAS CANCER; PERSONALIZED MEDICINE; PIK3CA GENE; PML RAR GENE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROMYELOCYTIC LEUKEMIA; PTEN GENE; REVIEW; TRIPLE NEGATIVE BREAST CANCER; TUMOR SUPPRESSOR GENE;

BIOLOGICAL MARKERS; HUMANS; INDIVIDUALIZED MEDICINE; NEOPLASMS; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS;

EID: 84860390334     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2011.121     Document Type: Review

References (105)

1. American Cancer Society. Lifetime Risk of Developing or Dying From Cancer [online], http://www.cancer.org/Cancer/CancerBasics/lifetime-probability-of- developing-or-dying-from-cancer (2010).
2. Yabroff, K. R., Warren, J. L. & Brown, M. L. Costs of cancer care in the USA: a descriptive review. Nat. Clin. Pract. Oncol. 4, 643-656 (2007). (Pubitemid 350020379)
3. Azorsa, D. O., et al. Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer. J. Transl. Med. 7, 43 (2009).
4. Schilsky, R. L. Personalized medicine in oncology: the future is now. Nat. Rev. Drug Discov. 9, 363-366 (2010).
5. Fine, B. M. & Amler, L. Predictive biomarkers in the development of oncology drugs: a therapeutic industry perspective. Clin. Pharmacol. Ther. 85, 535-538 (2009).
6. Duffy, M. J. & Crown, J. A personalized approach to cancer treatment: how biomarkers can help. Clin. Chem. 54, 1770-1779 (2008).
7. Park, J. W., et al. Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development. Clin. Cancer Res. 10, 3885-3896 (2004). (Pubitemid 38697625)
8. Cronin, M., et al. Analytical validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer. Clin. Chem. 53, 1084-1091 (2007). (Pubitemid 46867525)
9. Ward, D. G., et al. Identification of serum biomarkers for colon cancer by proteomic analysis. Br. J. Cancer 94, 1898-1905 (2006). (Pubitemid 43882582)
10. Sarker, D. & Workman, P. Pharmacodynamic biomarkers for molecular cancer therapeutics. Adv. Cancer Res. 96, 213-268 (2007).
11. Ratain, M. J., Schilsky, R. L., Conley, B. A. & Egorin, M. J. Pharmacodynamics in cancer therapy. J. Clin. Oncol. 8, 1739-1753 (1990). (Pubitemid 20334330)
12. August, J. Market watch: emerging companion diagnostics for cancer drugs. Nat. Rev. Drug Discov. 9, 351 (2010).
13. Sawyers, C. Targeted cancer therapy. Nature 432, 294-297 (2004). (Pubitemid 39551656)
14. Segal, N. H. & Saltz, L. B. Evolving treatment of advanced colon cancer. Annu. Rev. Med. 60, 207-219 (2009).
15. Badgwell, B. D., et al. Management of bevacizumab-associated bowel perforation: a case series and review of the literature. Ann. Oncol. 19, 577-582 (2008). (Pubitemid 351325682)
16. Goodsaid, F. & Papaluca, M. Evolution of biomarker qualification at the health authorities. Nat. Biotechnol. 28, 441-443 (2010).
17. Raftery, J. NICE and the challenge of cancer drugs. BMJ 338, b67 (2009).
18. Berns, K., et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12, 395-402 (2007). (Pubitemid 47539306)
19. Slamon, D. J., et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235, 177-182 (1987). (Pubitemid 17231334)
20. Dawood, S., et al. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J. Clin. Oncol. 28, 92-98 (2010).
21. Slamon, D. J., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783-792 (2001). (Pubitemid 32222155)
22. Hudis, C. A. Trastuzumab-mechanism of action and use in clinical practice. N. Engl. J. Med. 357, 39-51 (2007). (Pubitemid 47026733)
23. Bange, J., Zwick, E. & Ullrich, E. Molecular targets for breast cancer therapy and prevention. Nat. Med. 7, 548-552 (2001). (Pubitemid 32448320)
24. Romond, E. H., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 353, 1673-1684 (2005). (Pubitemid 41464706)
25. Piccart-Gebhart, M. J., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 353, 1659-1672 (2005). (Pubitemid 41464705)
26. Valabrega, G., Montemurro, F. & Aglietta, M. Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann. Oncol. 18, 977-984 (2007). (Pubitemid 47050487)
27. Suter, T. M., et al. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J. Clin. Oncol. 25, 3859-3865 (2007). (Pubitemid 47477261)
28. Muthuswamy, S. K. Trastuzumab resistance: all roads lead to SRC. Nat. Med. 17, 416-418 (2011).
29. Allison, M. The HER2 testing conundrum. Nat. Biotechnol. 28, 117-119 (2010).
30. Phillips, K. A., et al. Clinical practice patterns and cost effectiveness of human epidermal growth receptor 2 testing strategies in breast cancer patients. Cancer 115, 5166-5174 (2009).
31. Cuadros, M. & Villegas, M. Systematic review of HER2 breast cancer testing. Appl. Immunohistochem. Mol. Morphol. 17, 1-7 (2009).
32. Perez, E. A., et al. HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization. Mayo Clin. Proc. 77, 148-154 (2002). (Pubitemid 34118890)
33. Stone, R. M. Optimizing treatment of chronic myeloid leukemia: a rational approach. Oncologist 9, 259-270 (2004). (Pubitemid 38756875)
34. Deininger, M. W. & Druker, B. J. Specific targeted therapy of chronic myelogenous leukemia with imatinib. Pharmacol. Rev. 55, 401-423 (2003). (Pubitemid 37013211)
35. Wodarz, D. Heterogeneity in chronic myeloid leukaemia dynamics during imatinib treatment: role of immune responses. Proc. Biol. Sci. 277, 1875-1880 (2010).
36. Goozner, M. Drug developers unveil strategies aimed at imatinib-resistant CML. J. Natl Cancer Inst. 102, 593-595 (2010).
37. Breccia, M. Hematology: Nilotinib and dasatinib-new magic bullets for CML? Nat. Rev. Clin. Oncol. 7, 557-558 (2010).
38. Fuerst, M. L. FDA approves dasatinib for imatinib resistance and intolerance 3 weeks after enthusiastic recommendation from ODAC. Oncol. Times 28, 9-10 (2006).
39. Kantarjian, H., et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. 362, 2260-2270 (2010).
40. Breccia, M. & Alimena, G. Nilotinib: a second-generation tyrosine kinase inhibitor for chronic myeloid leukemia. Leuk. Res. 34, 129-134 (2010).
41. Kantarjian, H., et al. Dasatinib. Nat. Rev. Drug Discov. 5, 717-718 (2006). (Pubitemid 44323698)
42. Sawyers, C. L. Chronic myeloid leukemia. N. Engl. J. Med. 340, 1330-1340 (1999). (Pubitemid 29196596)
43. Harris, T. Gene and drug matrix for personalized cancer therapy. Nat. Rev. Drug Discov. 9, 660 (2010).
44. Weisberg, E., Manley, P. W., Cowan-Jacob, S. W., Hochhaus, A. & Griffin, J. D. Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat. Rev. Cancer 7, 345-356 (2007). (Pubitemid 46652483)
45. Terasawa, T., Dahabreh, I. & Trikalinos, T. A. BCR-ABL mutation testing to predict response to tyrosine kinase inhibitors in patients with chronic myeloid leukemia. PLoS Curr. 2, RRN1204 (2010).
46. Papadopoulos, N., Kinzler, K. W. & Vogelstein, B. The role of companion diagnostics in the development and use of mutation-targeted cancer therapies. Nat. Biotechnol. 24, 985-995 (2006). (Pubitemid 44215393)
47. Siddiqui, M. A. & Scott, L. J. Imatinib: a review of its use in the management of gastrointestinal stromal tumours. Drugs 67, 805-820 (2007). (Pubitemid 46535650)
48. Heinrich, M. C. Imatinib treatment of metastatic GIST: dont stop (believing). Lancet Oncol. 11, 910-911 (2010).
49. Heinrich, M. C., et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J. Clin. Oncol. 21, 4342-4349 (2003). (Pubitemid 46621810)
50. Ciardiello, F. & Tortora, G. EGFR antagonists in cancer treatment. N. Engl. J. Med. 358, 1160-1174 (2008).
51. Saltz, L. B., et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J. Clin. Oncol. 22, 1201-1208 (2004). (Pubitemid 41079832)
52. Lenz, H. J., et al. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J. Clin. Oncol. 24, 4914-4921 (2006).
53. Santini, D. Molecular predictive factors of response to anti-EGFR antibodies in colorectal cancer patients. Eur. J. Cancer Suppl. 6, 86-90 (2008).
54. Saif, M. W. Colorectal cancer in review: the role of the EGFR pathway. Expert Opin. Investig. Drugs 19, 357-369 (2010).
55. Lièvre, A., Blons, H. & Laurent-Puig, P. Oncogenic mutations as predictive factors in colorectal cancer. Oncogene 29, 3033-3043 (2010).
56. Linardou, H., et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol. 9, 962-972 (2008).
57. Karapetis, C. S., et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 359, 1757-1765 (2008).
58. Shankaran, V., Obel, J. & Benson, A. B. 3rd. Predicting response to EGFR inhibitors in metastatic colorectal cancer: current practice and future directions. Oncologist 15, 157-167 (2010).
59. Mack, G. S. FDA holds court on post hoc data linking KRAS status to drug response. Nat. Biotechnol. 27, 110-112 (2009).
60. Wolff, A. C., et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J. Clin. Oncol. 25, 118-145 (2007). (Pubitemid 350003059)
61. Gridelli, C., et al. Erlotinib in non-small cell lung cancer treatment: current status and future development. Oncologist 12, 840-849 (2007). (Pubitemid 47328227)
62. Oxnard, G. R. & Miller, V. A. Use of erlotinib or gefitinib as initial therapy in advanced NSCLC. Oncology (Williston Park) 24, 392-399 (2010).
63. Saijo, N. Targeted therapies: Tyrosine-kinase inhibitors-new standard for NSCLC therapy. Nat. Rev. Clin. Oncol. 7, 618-619 (2010).
64. Maemondo, M., et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N. Engl. J. Med. 362, 2380-2388 (2010).
65. Mitsudomi, T., et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 11, 121-128 (2010).
66. Lopez-Chavez, A. & Giaccone, G. Targeted therapies: Importance of patient selection for EGFR TKIs in lung cancer. Nat. Rev. Clin. Oncol. 7, 360-362 (2010).
67. Massarelli, E., et al. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin. Cancer Res. 13, 2890-2896 (2007). (Pubitemid 46849563)
68. Sasaki, T., Rodig, S. J., Chirieac, L. R. & Jnne, P. A. The biology and treatment of EML4-ALK non-small cell lung cancer. Eur. J. Cancer 46, 1773-1780 (2010).
69. Butrynski, J. E., et al. Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N. Engl. J. Med. 363, 1727-1733 (2010).
70. De Witt Hamer, P. C. Small molecule kinase inhibitors in glioblastoma: a systematic review of clinical studies. Neuro. Oncol. 12, 304-316 (2010).
71. Mellinghoff, I. K., Cloughesy, T. F. & Mischel, P. S. PTEN-mediated resistance to epidermal growth factor receptor kinase inhibitors. Clin. Cancer Res. 13, 378-381 (2007). (Pubitemid 46225339)
72. Mellinghoff, I. K., et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N. Engl. J. Med. 353, 2012-2024 (2005). (Pubitemid 41609094)
73. Diverio, D., Riccioni, R., Mandelli, F. & Lo Coco, F. The PML/RAR alpha fusion gene in the diagnosis and monitoring of acute promyelocytic leukemia. Haematologica 80, 155-160 (1995).
74. Soprano, D. R., Qin, P. & Soprano, K. J. Retinoic acid receptors and cancers. Annu. Rev. Nutr. 24, 201-221 (2004). (Pubitemid 38938791)
75. Lin, R. J. & Evans, R. M. Acquisition of oncogenic potential by RAR chimeras in acute promyelocytic leukemia through formation of homodimers. Mol. Cell 5, 821-830 (2000).
76. Freemantle, S. J., Spinella, M. J. & Dmitrovsky, E. Retinoids in cancer therapy and chemoprevention: promise meets resistance. Oncogene 22, 7305-7315 (2003). (Pubitemid 37487162)
77. Zhou, D. C., et al. Frequent mutations in the ligand-binding domain of PML-RARalpha after multiple relapses of acute promyelocytic leukemia: analysis for functional relationship to response to all-trans retinoic acid and histone deacetylase inhibitors in vitro and in vivo. Blood 99, 1356-1363 (2002).
78. Tang, X. H. & Gudas, L. J. Retinoids, retinoic acid receptors, and cancer. Annu. Rev. Pathol. 6, 345-364 (2011).
79. Kuendgen, A., et al. The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia. Cancer 106, 112-119 (2006). (Pubitemid 43032555)
80. De los Santos, M., Zambrano, A., Sánchez-Pacheco, A. & Aranda, A. Histone deacetylase inhibitors regulate retinoic acid receptor beta expression in neuroblastoma cells by both transcriptional and posttranscriptional mechanisms. Mol. Endocrinol. 21, 2416-2426 (2007). (Pubitemid 47529355)
81. Wooster, R. & Weber, B. L. Breast and ovarian cancer. N. Engl. J. Med. 348, 2339-2347 (2003). (Pubitemid 36638109)
82. Kaelin, W. G. Jr. The concept of synthetic lethality in the context of anticancer therapy. Nat. Rev. Cancer 5, 689-698 (2005). (Pubitemid 41486362)
83. Ashworth, A. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J. Clin. Oncol. 26, 3785-3790 (2008).
84. Amé, J. C., Spenlehauer, C. & de Murcia, G. The PARP superfamily. Bioessays 26, 882-893 (2004). (Pubitemid 39128102)
85. Farmer, H., et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917-921 (2005). (Pubitemid 40559006)
86. Yap, T. A., et al. First in human phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of KU-0059436 (Ku), a small molecule inhibitor of poly ADP-ribose polymerase (PARP) in cancer patients (p), including BRCA1/2 mutation carriers [abstract]. J. Clin. Oncol. 25 (Suppl.), a3529 (2007).
87. Ratnam, K. & Low, J. A. Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology. Clin. Cancer Res. 13, 1383-1388 (2007). (Pubitemid 46450426)
88. Foulkes, W. D., Smith, I. E. & Rein-Filho, J. S. Triple-negative breast cancer. N. Engl. J. Med. 363, 1938-1948 (2010).
89. OShaughnessy, J., et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N. Engl. J. Med. 364, 205-214 (2011).
90. Bath, C. Phase III results for PARP inhibitor iniparib quell optimism about new option for triple-negative metastatic breast cancer. The Asco Post [online], http://www.ascopost.com/articles/july-1-2011/iniparib-fails-to- improve-outcomes-in-triple-negative-breast-cancer (2011).
91. Hutchinson, L. Targeted therapies: PARP inhibitor olaparib is safe and effective in patients with BRCA1 and BRCA2 mutations. Nat. Rev. Clin. Oncol. 7, 549 (2010).
92. Miller, A. J. & Mihm, M. C. Jr. Melanoma. N. Engl. J. Med. 355, 51-65 (2006).
93. Flaherty, K. T., et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809-819 (2010).
94. Nazarian, R., et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468, 973-977 (2010).
95. Shi, H., Kong, X., Ribas, A. & Lo, R.S. Combinatorial treatments that overcome PDGFR?-driven resistance of melanoma cells to V600E B-RAF inhibition. Cancer Res. 71, 5067-5074 (2011).
96. Mullenders, J. & Bernards, R. Loss-of-function genetic screens as a tool to improve the diagnosis and treatment of cancer. Oncogene 28, 4409-4420 (2009).
97. Cully, M., You, H., Levine, A. J. & Mak, T. W. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat. Rev. Cancer 6, 184-192 (2006). (Pubitemid 43292562)
98. Iorns, E., et al. Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer. Cancer Cell 13, 91-104 (2008). (Pubitemid 351163160)
99. Fotheringham, S., et al. Genome-wide loss-of-function screen reveals an important role for the proteasome in HDAC inhibitor-induced apoptosis. Cancer Cell 15, 57-66 (2009).
100. Khan, O., et al. HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy. Proc. Natl Acad. Sci. USA 107, 6532-6537 (2010).
101. Stimson, L., Wood, V., Khan, O., Fotheringham, S. & La Thangue, N. B. HDAC inhibitor-based therapies and haematological malignancy. Ann. Oncol. 20, 1293-1302 (2009).
102. McConkey, D. Proteasome and HDAC: whos zooming who? Blood 116, 308-309 (2010).
103. Whitehurst, A. W., et al. Synthetic lethal screen identification of chemosensitizer loci in cancer cells. Nature 446, 815-819 (2007). (Pubitemid 46582032)
104. Shapiro, C. L., et al. Phase I trial of bortezomib (Velcade) in combination with paclitaxel in advanced solid tumor patients (pts) [abstract]. J. Clin. Oncol. 23 (Suppl.), a3104 (2005).
105. Young, R. C. Cancer clinical trials-a chronic but curable crisis. N. Engl. J. Med. 363, 306-309 (2010).